Cipla's Q4 profit crashed 55% but FDA approval for generic Ventolin HFA inhaler worth $100M+ a year sent stock up 8%. Three more inhalers pending.
Cipla reported one of its worst quarterly profits in recent years on 13 May. The next day the stock jumped 8%. The disconnect comes down to one product that is not an ordinary inhaler.
Profit after tax for the March 2026 quarter came in at Rs 555 crore, roughly 55% below the same period a year earlier. Revenue slipped 2.8% to Rs 6,540 crore ($687 million). The damage was concentrated in North America, where sales fell 26% to $155 million.
The headline numbers should have punished the stock. Instead, investors focused on what is coming next, not what just happened.
In April, Cipla received FDA approval for a facility in Massachusetts to manufacture a generic version of Ventolin HFA, one of the most-prescribed emergency-use asthma drugs in the world. The branded product, made by London-based GSK, controls more than half of the US rescue-inhaler market. Global sales for Ventolin HFA exceed $890 million.
One analyst who has tracked active pharma ingredients and US drug markets for over 15 years estimated that Cipla could capture over $100 million a year from the generic version alone. That single revenue stream, if realised, would more than offset the earnings miss.
The steep drop in North America revenue has a clear cause. Two highly profitable products – Revlimid (a cancer drug) and Lanreotide (a hormone drug) – disappeared from US shelves within three months. Together they accounted for 35–40% of Cipla's US sales, according to a former company executive. Their removal left a gap that the inhaler pipeline is now expected to fill.
Cipla's management hinted during the earnings call that three other inhaled products could receive FDA approval during the current financial year:
Combined, these three drugs open up a billion-dollar addressable market. AstraZeneca holds an Alpha Score of 53/100 (Mixed) in the healthcare sector, reflecting the competitive pressure generic entrants like Cipla bring to the branded franchise.
The simple read: current earnings do not matter because the pipeline will deliver massive incremental revenue. The better market read requires more scrutiny.
Investors are discounting a future where all four inhaler approvals materialise on schedule and generate the projected revenue. That assumption carries execution risk. FDA approval timelines can slip. Manufacturing quality issues can halt production. Competitors such as Dr Reddy's – which also reported a US sales decline this quarter – are pursuing similar generics.
Cipla’s Massachusetts facility just received its first FDA nod. Ramping up commercial-scale production for a metered-dose inhaler, a technically complex dosage form, takes time. Any delay in the three follow-on approvals would stretch the revenue ramp into 2027 or later.
The stock rallied on an event that has not yet generated revenue. The next 12 months will determine whether the market's forward look was astute or premature.
Cipla's story has shifted from a fading US generics business to an inhaler-driven recovery. The Q4 earnings miss is now a footnote. What matters is whether the FDA issues the remaining approvals on time.
Prepared with AlphaScala research tooling and grounded in primary market data: live prices, fundamentals, SEC filings, hedge-fund holdings, and insider activity. Each story is checked against AlphaScala publishing rules before release. Educational coverage, not personalized advice.